Since 1975, CBO has produced nonpartisan analyses of budgetary and economic issues in support of the Congress. In 2018, CBO completed 947 formal cost estimates, 70 analytic reports and working papers, and many other products.
In 2015, brand-name specialty drugs accounted for about 30 percent of net spending on prescription drugs under Medicare Part D and Medicaid, but they accounted for only about 1 percent of all prescriptions dispensed in each program.
CBO reports annually to the Congress on programs funded for the current fiscal year whose authorizations of appropriations have expired and on programs whose authorizations will expire during the current fiscal year.
The federal budget deficit was $537 billion for the first five months of fiscal year 2019, CBO estimates, $146 billion more than the deficit recorded during the same period last year.
The effects on direct spending and revenues of laws enacted in 2017 are estimated to add $1.5 trillion to federal deficits over the 2017–2027 period; laws enacted in 2018 are projected to have little net effect over the 2018–2028 period.